Australia · Delayed Price · Currency is AUD OncoSil Medical Statistics
Total Valuation
OncoSil Medical has a market cap or net worth of AUD 35.60 million. The enterprise value is 29.14 million.
| Market Cap | 35.60M |
| Enterprise Value | 29.14M |
Important Dates
The next estimated earnings date is Friday, November 27, 2026.
| Earnings Date | Nov 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
OncoSil Medical has 36.70 million shares outstanding. The number of shares has increased by 107.26% in one year.
| Current Share Class | 36.70M |
| Shares Outstanding | 36.70M |
| Shares Change (YoY) | +107.26% |
| Shares Change (QoQ) | +43.93% |
| Owned by Insiders (%) | 4.55% |
| Owned by Institutions (%) | 30.71% |
| Float | 27.22M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.00 |
| PB Ratio | 7.13 |
| P/TBV Ratio | 7.13 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 5.73 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.77, with a Debt / Equity ratio of 0.00.
| Current Ratio | 1.77 |
| Quick Ratio | 1.68 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.00 |
| Interest Coverage | -655.59 |
Financial Efficiency
Return on equity (ROE) is -268.15% and return on invested capital (ROIC) is -168.20%.
| Return on Equity (ROE) | -268.15% |
| Return on Assets (ROA) | -78.85% |
| Return on Invested Capital (ROIC) | -168.20% |
| Return on Capital Employed (ROCE) | -220.09% |
| Weighted Average Cost of Capital (WACC) | 11.04% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.58 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -40.85% in the last 52 weeks. The beta is 1.23, so OncoSil Medical's price volatility has been higher than the market average.
| Beta (5Y) | 1.23 |
| 52-Week Price Change | -40.85% |
| 50-Day Moving Average | 1.18 |
| 200-Day Moving Average | 0.82 |
| Relative Strength Index (RSI) | 40.51 |
| Average Volume (20 Days) | 159,376 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, OncoSil Medical had revenue of AUD 5.09 million and -10.86 million in losses. Loss per share was -0.48.
| Revenue | 5.09M |
| Gross Profit | 2.73M |
| Operating Income | -11.01M |
| Pretax Income | -10.86M |
| Net Income | -10.86M |
| EBITDA | -11.00M |
| EBIT | -11.01M |
| Loss Per Share | -0.48 |
Balance Sheet
The company has 6.48 million in cash and 14,782 in debt, with a net cash position of 6.46 million or 0.18 per share.
| Cash & Cash Equivalents | 6.48M |
| Total Debt | 14,782 |
| Net Cash | 6.46M |
| Net Cash Per Share | 0.18 |
| Equity (Book Value) | 5.00M |
| Book Value Per Share | 0.16 |
| Working Capital | 4.07M |
Cash Flow
In the last 12 months, operating cash flow was -10.47 million and capital expenditures -1,455, giving a free cash flow of -10.47 million.
| Operating Cash Flow | -10.47M |
| Capital Expenditures | -1,455 |
| Depreciation & Amortization | 10,587 |
| Net Borrowing | -55,162 |
| Free Cash Flow | -10.47M |
| FCF Per Share | -0.29 |
Margins
Gross margin is 53.68%, with operating and profit margins of -216.41% and -213.40%.
| Gross Margin | 53.68% |
| Operating Margin | -216.41% |
| Pretax Margin | -213.40% |
| Profit Margin | -213.40% |
| EBITDA Margin | -216.20% |
| EBIT Margin | -216.41% |
| FCF Margin | n/a |
Dividends & Yields
OncoSil Medical does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -107.26% |
| Shareholder Yield | -107.26% |
| Earnings Yield | -30.50% |
| FCF Yield | -29.42% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on June 3, 2025. It was a reverse split with a ratio of 0.0025.
| Last Split Date | Jun 3, 2025 |
| Split Type | Reverse |
| Split Ratio | 0.0025 |
Scores
OncoSil Medical has an Altman Z-Score of -16.22 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -16.22 |
| Piotroski F-Score | 4 |